Steve Bryson, PhD, science writer —

Aubagio (teriflunomide) failed to significantly reduce relapses in children with multiple sclerosis (MS), but two years of treatment decreased the number of brain lesions on MRI scans, according to the final results of the Phase 3 TERIKIDS clinical trial. Importantly, the lack of a signficantly lower relapse rate…

Low vitamin D levels in the bloodstream are associated with slower information processing speeds in people with early-stage multiple sclerosis (MS), a study suggests. “Our data support the hypothesis that vitamin D is involved in cognition in MS,” its researchers concluded. The study, “Serum Vitamin D as…

Using robotic devices during gait training can improve walking abilities in people with multiple sclerosis (MS), particularly among those with severe disability, a review of 17 studies has found. However, the benefits lasted only a few months, suggesting that patients need regular training to maintain the improvements. The study,…

A single dose of NVG-291, a potential nerve repair therapy for multiple sclerosis (MS), was safe and well-tolerated among healthy volunteers in a Phase 1 safety trial, and was found to have favorable pharmacological properties, new data show. Given the positive results thus far, a safety committee supervising…

Extracellular vesicles or EVs — tiny sacs of material excreted by cells — that have been coated with protein receptors were found to safely reduce disease progression in a mouse model of multiple sclerosis (MS). Researchers at the Karolinska Institutet, in Sweden, coated these vesicles with receptors that block pro-inflammatory…

Mindfulness-based interventions (MBIs) helped people with multiple sclerosis (MS) cope with symptoms, and many said they would recommend these practices to others living with MS, according to a review of published studies related to patients’ experiences. The participants reported the benefits of a shared experience, but stressed the importance…

One year of Ocrevus (ocrelizumab) treatment does not increase the risk for a rare brain infection — called progressive multifocal leukoencephalopathy (PML) — in people with multiple sclerosis (MS), a study suggests. The study, “Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during…

Mutations in the John Cunningham virus may serve as an early predictor for a rare brain infection in multiple sclerosis patients receiving Tysabri (natalizumab), a study suggests. However, more research is required to investigate the specific mutations in the viral VP1 gene, and validate the risk of the…

TG Therapeutics  has applied to the U.S. Food and Drug Administration (FDA) for approval of ublituximab, the company’s investigational anti-CD20 monoclonal antibody therapy for relapsing forms of multiple sclerosis (RMS). Its application was based on data from the ULTIMATE 1 (NCT03277261) and ULTIMATE 2 (NCT03277248) Phase…

An investigational immunotherapy, ATA188 showed it could reverse disability and improve exercise capacity in people with progressive forms of multiple sclerosis (MS), Atara Biotherapeutics, its developer, reported in an update on a Phase 1 trial and its long-term extension study. EMBOLD trial findings based on MRI brain imaging…

Depression in multiple sclerosis (MS) patients greatly raises their risk of vascular disease and death by any cause, a study that compared this patient group with other patients and a matched public reported. Its researchers recommended further work to determine “whether effectively treating depression” might lower these risks for these…

  An extended-release formulation of amantadine, ADS-5102 was significantly more effective than a placebo at increasing walking speed in multiple sclerosis (MS) patients who had difficulty with this, particularly younger patients with a shorter disease course, the INROADS Phase 3 trial demonstrated. Further clinical work on this investigative…

In people with early-stage multiple sclerosis (MS), the presence of high levels of neurofilament light chain (sNfL) protein in the bloodstream combined with thinning of the retina is a strong indicator of future disease activity, a recent study demonstrates. “Our findings encourage the application of both sNfL and retinal…

A real-world study confirmed the effectiveness and safety of interferon beta-1b in treating older adults with multiple sclerosis (MS), those over the age of 40. “These findings from a real-world setting are promising and demonstrate the positive benefit-risk ratio for [interferon beta-1b] in this study population of middle-aged and…

A new clinical trial launched by the National Institutes of Health (NIH) is evaluating the impact of an extra dose of an approved or authorized COVID-19 vaccine in people with multiple sclerosis (MS) and other autoimmune diseases who did not properly respond to an original vaccine regimen. Approximately 600 people will…

Sonoma Biotherapeutics has raised $265 million in investment funding to support the development and production of novel immune T-cell therapies to treat severe autoimmune and inflammatory diseases, such as multiple sclerosis (MS). “We are ushering in a new era of medicine, using immune cells as living therapies that…

Clene’s investigational oral therapy CNM-Au8 improved energy metabolism in the brain of adults with relapsing-remitting multiple sclerosis (RRMS), according to top-line results from the REPAIR-MS trial. This open-label Phase 2 pilot study (NCT03993171), taking place in Texas, is running in parallel with REPAIR-PD, another Phase 2…

High-dose biotin aided walking speed in people with progressive multiple sclerosis after 12 to 15 months as an add-on treatment, an analysis of placebo-controlled clinical trials shows. However, the therapy failed to improve other measures of disability, and was associated with inaccurate lab test results caused by high levels…

Accessing healthcare providers knowledgeable about multiple sclerosis (MS) and being able to afford additional services to improve overall health were the most pressing healthcare concerns among Canadians with the condition, a survey suggests. “These findings provide healthcare planners prioritized concerns and a profile of [people with MS] that have…

The low-fat Swank diet and the Wahls elimination diet reduced fatigue and improved quality of life after three months for people with relapsing-remitting multiple sclerosis (RRMS), a clinical trial has found. “It’s encouraging that fatigue was reduced and quality of life improved in both groups,” Bruce Bebo, PhD, from…

Tysabri (natalizumab) given every six weeks was as safe and effective over nearly 1.5 years of use as its approved four-week dosing in people with relapsing-remitting multiple sclerosis (RRMS), according to top-line data from the Phase 3b NOVA study. Tysabri is typically administered every four weeks, or about…

Genetic susceptibility to multiple sclerosis (MS) depends on an individual’s particular combination of multiple risk variants, a study reveals. The study, “Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions,” was published in the journal BMC Medical…

A component of yeast cell walls — called MGCP — prevented disease in a mouse model of multiple sclerosis (MS) by activating anti-inflammatory immune T-cells while suppressing inflammatory T-cells, a study showed. This work also supporting the microbiome’s role in affecting inflammation in autoimmune diseases like MS. “We have…

A potential anti-inflammatory treatment, xB3-IL-1RA was able to reach the central nervous system of a rodent model of multiple sclerosis (MS), and with repeat doses delay disease onset and ease clinical symptoms, according to the investigational therapy’s developer Bioasis Technologies. These findings support the utility of Bioasis’ xB3 peptide…

Nvidia announced the launch of the U.K.’s most powerful supercomputer — called Cambridge-1 — which uses a combination of artificial intelligence (AI) and simulation to help scientists to better understand complex diseases such as multiple sclerosis (MS) and to design new therapeutics. Cambridge-1 is the first supercomputer designed…

High-potency therapies are more effective at reducing the frequency of symptom relapses in people with secondary progressive multiple sclerosis (SPMS) than low-potency medications, a 10-year study showed. Notably, there was no difference in the effectiveness of either high- or low-potency medicines to limit the progression of disability. “When the…

Using high-efficacy therapies as a first treatment for multiple sclerosis (MS) patients significantly increases the likelihood of having no evidence of disease activity after one and two years, compared to using moderately effective therapies, according to a real-world study of Norwegian patients. However, with each additional attempted treatment, the…

The enzyme TET1, which is progressively lost with age, is essential to activate genes needed to repair myelin — the sheath around nerve cells that is damaged in people with multiple sclerosis (MS) — a study in mice has found. The…

John and Catherine Seibyl, both alumni of Case Western Reserve University (CWRU) in Ohio, have pledged $7.5 million to the university to advance multidisciplinary research into multiple sclerosis (MS) and other neurodegenerative diseases. The funds will be shared strategically between CWRU’s School of Medicine and the Frances Payne Bolton…

Gilenya (fingolimod) at its approved 0.5 mg daily dose continues to be the optimal dose for people with relapsing-remitting MS (RRMS), a systematic review of 11 clinical trials confirmed. A 0.25 mg/day dose, however, also showed improvement over placebo in MRI outcomes and patient satisfaction, the researchers noted, and further…